Biotest

Biotest, headquartered in Germany and operating within the Pharmaceutical Preparation Manufacturing industry, reported a total of approximately 130.4 billion kg CO2e for 2025. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. In 2025, Scope 1 emissions were approximately 17.5 billion kg CO2e, while Scope 2 emissions, based on market-based reporting, amounted to approximately 26 billion kg CO2e. Scope 3 emissions for the same year were approximately 86.9 billion kg CO2e, with purchased goods and services representing the largest contributor within this scope, at approximately 60.1 billion kg CO2e.

In the preceding year, 2024, Biotest's total emissions were approximately 134.5 billion kg CO2e. This breakdown included Scope 1 emissions of approximately 17 billion kg CO2e, Scope 2 emissions (market-based) of approximately 25.3 billion kg CO2e, and Scope 3 emissions of approximately 92.2 billion kg CO2e. A significant portion of the 2024 Scope 3 emissions was attributed to purchased goods and services, totalling approximately 64.2 billion kg CO2e.

For 2023, total emissions stood at approximately 139.2 billion kg CO2e, comprising Scope 1 emissions of about 15.2 billion kg CO2e, Scope 2 emissions (market-based) of approximately 21.9 billion kg CO2e, and Scope 3 emissions of about 102 billion kg CO2e. Data for Scope 3's purchased goods and services was missing for this reporting year.

Biotest's emissions data is inherited from its parent organisation, Grifols, S.A., reflecting a corporate family relationship. The company has disclosed its Scope 1, 2, and 3 emissions, with specific upstream categories reported. Currently, there are no specific reduction targets or climate pledges publicly available for Biotest.